SynthesisEndocrine, metabolic & immune disorders drug targets2026
Probiotic Supplementation and its Potential Benefits in Type 2 Diabetes: A Meta-analysis.
Synthesis in Endocrine, metabolic & immune disorders drug targets, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThis meta-analysis aims to evaluate the efficacy and safety of probiotic supplementation as an adjunct to standard therapy in patients with type 2 diabetes (T2D), with a focus on its effects on plasma glucose, HbA1c, and insulin levels.
methodsSpecific keywords such as "Type 2 Diabetes", "Probiotics", and "Blood Sugar" were employed to identify relevant clinical and randomized controlled trials. A comprehensive search of PubMed, Scopus, and Web of Science, conducted between September 2010 and October 2024, retrieved 48 studies, of which only 9 met the predefined inclusion criteria. Studies were excluded if they did not involve patients with T2D, failed to specify the probiotic strains used, lacked a placebo-controlled arm, were not written in English, were not freely accessible, or did not report outcomes of interest.
resultsThree separate meta-analyses were conducted to evaluate the primary and secondary outcomes of interest: plasma glucose, HbA1c, and insulin concentrations. Each analysis revealed statistically significant effects. The magnitude of the effect of probiotic supplementation in patients with T2D is expressed by a promising reduction in fasting plasma glucose levels (MD = -17.68; 95% CI: -21.72 to -13.63; p < 0.0001; I DISCUSSION AND
conclusionThis meta-analysis included a total of 649 patients with T2D, who showed a reduction in levels of some clinical indicators at the end of the intervention period. These findings provide evidence supporting the use of probiotic supplementation as an adjunct to standard therapy for the management of this condition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.